Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Parallel-Group Study of E7090 Pharmacokinetics in Hepatic Impairment vs Healthy Subjects
jRCT2080225113Phase 1Recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tasurgratinib in hepatic impairment (3 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Primary pharmacokinetic parameters of E7090 and Primary pharmacokinetic parameters of E7090 metabolite. Started Mar 2020; status: recruiting.
02
Drugs
tasurgratinib
03
Conditions
hepatic impairment
Beyond the preview
Go deeper on jRCT2080225113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225113.